Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab

Indian Pediatr. 2020 Jul 15;57(7):681-683. doi: 10.1007/s13312-020-1901-z. Epub 2020 May 10.

Authors

S Balasubramanian¹, T M Nagendran², B Ramachandran³, A V Ramanan⁴

Affiliations

¹ Department of Pediatrics, Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India.
² Pediatric Intensive Care Unit, Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India. nagupeds@gmail.com.
³ Pediatric Intensive Care Unit, Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India.
⁴ Department of Pediatric Rheumatology; Bristol Royal Hospital for Children, Bristol, UK and Translational Health Sciences, University of Bristol, UK.

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Betacoronavirus*
COVID-19
Child
Coronavirus Infections / complications*
Coronavirus Infections / diagnosis
Coronavirus Infections / therapy
Humans
Immunoglobulins, Intravenous / therapeutic use*
Immunologic Factors / therapeutic use*
Male
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / therapy
SARS-CoV-2
Systemic Inflammatory Response Syndrome / diagnosis
Systemic Inflammatory Response Syndrome / therapy*
Systemic Inflammatory Response Syndrome / virology

Substances

Antibodies, Monoclonal, Humanized
Immunoglobulins, Intravenous
Immunologic Factors
tocilizumab